C-SLUPYOXLO
mitochondrial function, cellular function, bioactive compounds
modulating
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-SLUP
C-SLUPC-SLUPmitochondrial function, cellular function, bioactive compounds
0-100 chain-logic scale · 15 dimensions · scored on public evidence
YOXLO mitochondrial function, cellular function, bioactive compounds
YOXLO is a Dutch longevity startup building a proprietary healthspan intervention, Youniqor, around a centenarian-inspired thesis that mitochondrial function, cellular resilience, and inflammatory control, especially NLRP3-linked immune signaling, can be modulated to preserve strength, cognition, independence, and immune function with age. The evidence supports a real company, named team, patents, a 2024 review by founder Stef Verlinden, and 2025 XPRIZE Healthspan semifinalist status, but not convincing efficacy: the intervention evidence here is mostly company claims, review-level argument, and patent positioning rather than disclosed clinical outcomes.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
YOXLO — Translational · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic